OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells

Tomoyasu,Chihiro; Kikuchi,Ken; Kaneda,Daisuke; Yagyu,Shigeki; Miyachi,Mitsuru; Tsuchiya,Kunihiko; Iehara,Tomoko; Sakai,Toshiyuki; Hosoi,Hajime

doi:10.3892/or.2018.6813

OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells

Authors:
- Chihiro Tomoyasu
- Ken Kikuchi
- Daisuke Kaneda
- Shigeki Yagyu
- Mitsuru Miyachi
- Kunihiko Tsuchiya
- Tomoko Iehara
- Toshiyuki Sakai
- Hajime Hosoi
View Affiliations

Affiliations: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan, Department of Molecular‑Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
Published online on: October 22, 2018 https://doi.org/10.3892/or.2018.6813
Pages: 643-649

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rhabdomyosarcoma (RMS) is an aggressive pediatric cancer of musculoskeletal origin. Despite multidisciplinary approaches, such as surgical resection, irradiation, and intensive chemotherapy, adopted for its treatment, the prognosis of patients with high‑risk RMS remains poor. Thus, molecularly targeted therapies are required to improve patient survival and minimize side effects. Histone deacetylases (HDACs) modify transcription by deacetylation of the lysine residues in chromatin histone tails and several non‑histone proteins. HDAC inhibitors, classes of compounds targeted to various HDAC proteins, are being studied for their roles in several types of cancers in a rigorous manner. This study aimed to investigate the potential of a novel HDAC inhibitor, OBP‑801, as a therapeutic agent for the treatment of RMS. We used 8 RMS cell lines in this study. Protein expression patterns, cell proliferation, cell cycle status, and apoptosis in RMS cells after OBP‑801 treatment in vitro were investigated. We also studied the antitumor activity of OBP‑801 in an in vivo xenograft mouse model. We observed cell cycle arrest at the M‑phase and apoptosis in all RMS cell lines after exposure to pharmacological levels of OBP‑801 for 24 h. Immunofluorescence staining revealed that OBP‑801 may induce mitotic catastrophe via chromosome misalignment and reduced survivin expression, ultimately leading to apoptosis. Our results demonstrated that the novel HDAC inhibitor OBP‑801 was an effective inhibitor of RMS cell line proliferation and may be a potent therapeutic option for RMS.

View Figures

View References

1	Merlino G and Helman LJ: Rhabdomyosarcoma-working out the pathways. Oncogene. 18:5340–5348. 1999. View Article : Google Scholar : PubMed/NCBI
2	Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, et al: Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: A report from the Children's Oncology Group. Am J Pathol. 174:550–564. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelon LD, Hampton ST, Michalek JE, Rubin BP, Fields AP and Keller C: Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene. 32:286–295. 2013. View Article : Google Scholar : PubMed/NCBI
4	Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tsuchiya K, Iehara T and Hosoi H: Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res. 15:4077–4084. 2009. View Article : Google Scholar : PubMed/NCBI
5	Sokolowski E, Turina CB, Kikuchi K, Langenau DM and Keller C: Proof-of-concept rare cancers in drug development: The case for rhabdomyosarcoma. Oncogene. 33:18772014. View Article : Google Scholar : PubMed/NCBI
6	Minucci S and Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
7	Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 5:769–784. 2006. View Article : Google Scholar : PubMed/NCBI
8	Khabele D, Son DS, Parl AK, Goldberg GL, Augenlicht LH, Mariadason JM and Montgomery RV: Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer Biol Ther. 6:795–801. 2007. View Article : Google Scholar : PubMed/NCBI
9	Strait KA, Warnick CT, Ford CD, Dabbas B, Hammond EH and Ilstrup SJ: Histone deacetylase inhibitors induce G₂-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad. Mol Cancer Ther. 4:603–611. 2005. View Article : Google Scholar : PubMed/NCBI
10	Khan O and La Thangue NB: HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol. 90:85–94. 2012. View Article : Google Scholar : PubMed/NCBI
11	West AC and Johnstone RW: New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 124:30–39. 2014. View Article : Google Scholar : PubMed/NCBI
12	Porcu P and Wong HK: We should have a dream: Unlocking the workings of the genome in cutaneous T-cell lymphomas. Clin Lymphoma Myeloma. 9:409–411. 2009. View Article : Google Scholar : PubMed/NCBI
13	Mann BS, Johnson JR, Cohen MH, Justice R and Pazdur R: FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 12:1247–1252. 2007. View Article : Google Scholar : PubMed/NCBI
14	Jain S and Zain J: Romidepsin in the treatment of cutaneous T-cell lymphoma. J Blood Med. 2:37–47. 2011.PubMed/NCBI
15	Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J, et al: Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys. 78:237–245. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM and LaQuaglia MP: Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res. 9:5749–5755. 2003.PubMed/NCBI
17	Abraham J, Nuñez-Álvarez Y, Hettmer S, Carrió E, Chen HI, Nishijo K, Huang ET, Prajapati SI, Walker RL, Davis S, et al: Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev. 28:1578–1591. 2014. View Article : Google Scholar : PubMed/NCBI
18	Shindoh N, Mori M, Terada Y, Oda K, Amino N, Kita A, Taniguchi M, Sohda KY, Nagai K, Sowa Y, et al: YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol. 32:545–555. 2008.PubMed/NCBI
19	Kubo K, Naoe T, Utsumi KR, Ishiguro Y, Ueda K, Shiku H and Yamada K: Cytogenetic and cellular characteristics of a human embryonal rhabdomyosarcoma cell line, RMS-YM. Br J Cancer. 63:879–884. 1991. View Article : Google Scholar : PubMed/NCBI
20	Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y, Yagyu S, Tsubai-Shimizu S, Miyachi M, Iehara T, et al: Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun. 365:568–574. 2008. View Article : Google Scholar : PubMed/NCBI
21	Kikuchi K, Hettmer S, Aslam MI, Michalek JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ and Keller C: Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet. 10:e10041072014. View Article : Google Scholar : PubMed/NCBI
22	Nishijo K, Hosoyama T, Bjornson CR, Schaffer BS, Prajapati SI, Bahadur AN, Hansen MS, Blandford MC, McCleish AT, Rubin BP, et al: Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J. 23:2681–2690. 2009. View Article : Google Scholar : PubMed/NCBI
23	Marks PA, Richon VM, Miller T and Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res. 91:137–168. 2004. View Article : Google Scholar : PubMed/NCBI
24	Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X and Marks PA: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
25	Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, et al: The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol Cell Biol. 30:1171–1181. 2010. View Article : Google Scholar : PubMed/NCBI
26	Bose P, Dai Y and Grant S: Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights. Pharmacol Ther. 143:323–336. 2014. View Article : Google Scholar : PubMed/NCBI
27	Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al: Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25:486–551. 2018. View Article : Google Scholar : PubMed/NCBI
28	Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: A molecular definition. Oncogene. 23:2825–2837. 2004. View Article : Google Scholar : PubMed/NCBI
29	Vitale I, Galluzzi L, Castedo M and Kroemer G: Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 12:385–392. 2011. View Article : Google Scholar : PubMed/NCBI
30	Cornago M, Garcia-Alberich C, Blasco-Angulo N, Vall-Llaura N, Nager M, Herreros J, Comella JX, Sanchis D and Llovera M: Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis. 5:e14352014. View Article : Google Scholar : PubMed/NCBI
31	Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, Phelan C and Lazar MA: A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev. 20:2566–2579. 2006. View Article : Google Scholar : PubMed/NCBI
32	Nalawansha DA, Gomes ID, Wambua MK and Pflum MKH: HDAC inhibitor-induced mitotic arrest ss mediated by Eg5/KIF11 acetylation. Cell Chem Biol. 24:481–492. 2017. View Article : Google Scholar : PubMed/NCBI
33	Aljaberi AM, Webster JR and Wheatley SP: Mitotic activity of survivin is regulated by acetylation at K129. Cell Cycle. 14:1738–1747. 2015. View Article : Google Scholar : PubMed/NCBI